FDA-approved drug could be used to treat Ebola, study shows
August 12, 2019Sales and Marketing Ebolas, FDA, Romark, nitazoxanide, pharma, virus
The FDA-approved anti-parasitic drug nitazoxanide could be used as a treatment for Ebola, according to researchers from the Boston Children’s …
EU unprepared for no-deal Brexit, health experts warn
August 12, 2019Sales and Marketing EU, Euroepan Union, UK, brexit, pharma
European health experts have warned that a no-deal Brexit could worsen medicines shortages in the European Union. Speaking to Reuters, …
Senators call on FDA to use “forceful response” against Novartis over faulty data scandal
August 12, 2019Sales and Marketing AveXis, Bernie Sanders, Elizabeth Warren, FDA, Novartis, Zolgensma
Five senators, including presidential candidates Bernie Sanders and Elizabeth Warren, have condemned Novartis for using “falsified data… to obtain approval …
Court sides with Amgen in Sandoz’ challenge over patent on Enbrel
August 12, 2019Sales and Marketing Enbrel, IP, Novartis Amgen, court, patent, pharma
A US court has sided with Amgen in a legal battle over the patent on blockbuster rheumatoid arthritis drug Enbrel. …
Top Ten most popular articles on Pharmafile.com this week!
August 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, CAR T, CAR-T, Eli Lilly, Lexicon, Medicare, Novartis, Pfizer, Sanofi, pharma
This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …
MS drug boosts effectiveness of cancer therapy in treating glioblastoma, study shows
August 9, 2019Medical Communications MS, brain cancer, glioblastoma, oncology, pharma
The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …
Scientists use duoCAR-T therapy to fight HIV
August 9, 2019Medical Communications AIDS, CAR-T therapy, HIV, health, immunotherapy, pharma
Researchers from the University of Pittsburgh, working with the biotech Lentigen, have found that an advanced form of CAR-T therapy …
AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial
August 9, 2019Medical Communications AstraZeneca, Cancer, Tagrisso, lung cancer, oncology, pharma
AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …
Bayer buys BlueRock Therapeutics for $600 million
August 9, 2019Medical Communications Bayer, BlueRock, acquisitions, cell therapies, pharma
Bayer has entered into an agreement to fully acquire engineered cell therapy firm BlueRock Therapeutics in a deal worth $600 …
Transgene terminates oncolytic IO combo trial in advanced liver cancer
August 8, 2019Research and Development Cancer, Transgene, clinical trials, liver cancer, pharma
Biotech firm Transgene has announced its decision to terminate a study investigating the efficacy of its oncolytic immunotherapy product Pexa-Vec …
Medicare will cover CAR-T therapies in United States
August 8, 2019Sales and Marketing CAR-T therapies, Cancer, Gilead, Kymriah, Medicare, Novartis, keytruda, pharma
Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and …
Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund
August 8, 2019Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma
MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …
Gilead’s PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says
August 8, 2019Research and Development AIDS, Gilead, HIV, PrEP, descovy, pharma
Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men …
Rhythm Pharma’s obesity drug shows positive results in two Phase 3 trials
August 8, 2019Research and Development Rhythm pharma, clinical trial, health, obesity, pharma
Rhythm Pharma’s obesity drug setmelanotide achieved positive results in two pivotal Phase 3 trials. In both studies, setmelanotide met its …
Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis
August 7, 2019Research and Development Dupixent, Sanofi, atopic dermatitis, pharma
As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …
AstraZeneca’s Lynparza meets primary endpoint in Phase 3 prostate cancer trial
August 7, 2019Research and Development Lynpraza, PARP inhibitor, lynparza, pharma, prostate cancer
AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic …
NICE recommends Pierre Fabre’s Nerlynx in adjuvant HER2+ breast cancer
August 7, 2019Research and Development, Sales and Marketing Cancer, NCIE, NHS, Nerlynx, Pierre Fabre, UK, breast cancer
Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human …
Medicinal cannabis company Spectrum makes first shipment into UK
August 7, 2019Research and Development Spectrum, UK, cannabis, medicinalcannabis, pharma
Medicinal cannabis company Spectrum Europe has made its first shipment of cannabis into the UK, making it one of the …
Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma
August 7, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma
Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …
Troy Robinson promoted to managing director of Chugai Pharma Europe
August 6, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Troy Robinson has been taken on as the new managing director of Chugai Pharma Europe. Mike Crosher will succeed him …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
